NASDAQ · IRIX
IRIDEX Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IRIX: Nov 10, 2026
IRIDEX Corporation Common Stock is estimated to report earnings on 11/10/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.04. The reported EPS for the same quarter last year was $-0.09.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Dec 2026 | $0.02 | $0.02 | $0.02 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · Zacks · Fintel- RTTNews · Oct 12, 7:43 AM EDTIridex Reports Sustained Glaucoma Benefits With MicroPulse Laser Therapy At Two Years(RTTNews) – Iridex Corporation (IRIX) announced the publication of a two-year independent clinical study reporting sustained reductions in intraocular pressure (IOP) and a lower medication burden following treatment with its MicroPulse transscleral laser therapy (TLT) in patients
- The Motley Fool · Aug 25, 6:59 PM EDTIRIDEX (IRIX) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 25, 1:43 PM EDTIRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%IRIX's Q2 loss per share widens year over year and revenues decline as Middle East disruptions and reduced sell-through in China weigh on retina sales, offsetting continued growth in the Cyclo G6 product family.
- RTTNews · Aug 19, 4:12 AM EDTIridex Posts Q2 Results, Glaucoma Segment Shows Strength(RTTNews) – Iridex Corporation (IRIX), a provider of laser-based medical systems for glaucoma and retinal disease treatment, reported second-quarter 2026 financial results, reflecting mixed performance across its product lines.
- RTTNews · Jul 20, 11:45 AM EDTIridex Expands EyeProGPO Offering With EndoProbe Handpieces(RTTNews) – Iridex Corporation (IRIX), provider of laser-based medical systems for glaucoma and retinal diseases, has expanded its EyeProGPO product portfolio to include the company's EndoProbe Handpieces.
- Zacks · May 25, 12:59 PM EDTIRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product GrowthIRIDEX posts a narrower year-over-year net loss per share in Q1'26 as strong glaucoma product sales and lower operating costs helped offset weakness in retina sales and supply-chain disruptions.
- The Motley Fool · May 19, 6:03 PM EDTIridex (IRIX) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Apr 20, 2:27 AM EDTThe Zacks Analyst Blog Microsoft, AbbVie, BHP, CBL & Associates Properties and IRIDEXMicrosoft, AbbVie and BHP anchor today???s top analyst reports, highlighting AI growth, drug pipeline strength and rising commodity output shaping outlooks.
- Zacks · Apr 17, 5:16 PM EDTTop Analyst Reports for Microsoft, AbbVie & BHPMicrosoft rides AI and Azure growth, but slowing cloud guidance, capacity limits, and rising competition cast a shadow on its momentum.
- Zacks · Apr 1, 1:23 PM EDTIridex's Q4 Loss Narrows Year Over Year on Retina Sales GrowthIRIX incurs narrower year-over-year loss per share in Q4 as growth in retina systems and glaucoma probes boosts revenues, though margins remain pressured by higher costs.
- The Motley Fool · Mar 26, 5:55 PM EDTIRIDEX (IRIX) Q4 2025 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Feb 24, 8:37 PM ESTIRIDEX (IRIX) Price Target Increased by 50.00% to 3.06The average one-year price target for IRIDEX (NasdaqCM:IRIX) has been revised to $3.06 / share. This is an increase of 50.00% from the prior estimate of $2.04 dated September 23, 2024. The price target is an average of many targets provided by analysts. The la
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for IRIDEX Corporation from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.